Trial Profile
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) a Non-interventional Trial With Aromasin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms FAST
- Sponsors Pfizer
- 24 Jul 2010 Actual patient number is 980 according to ClinicalTrials.gov.
- 22 Jul 2010 Primary outcome amended as reported by ClinicalTrials.gov.
- 23 Jan 2010 New trial record